VolitionRx Limited announced the signing of a global supply agreement with a market leader in pet healthcare. Through Volition's supply agreement, the Company is engaged as a worldwide provider of the Nu.Q® Vet Cancer Test through its reference laboratory network for cancer indications in animal health. There are approximately 84 million pet dogs in the United States and just under 50% of dogs will have at least one veterinary care visit per annum which Volition believes will provide an incredible opportunity to screen those senior dogs (over 7 years) and breeds at risk of cancer from 4 years and upwards.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7236 USD | +0.49% | -8.04% | +0.92% |
05-14 | Transcript : VolitionRx Limited, Q1 2024 Earnings Call, May 14, 2024 | |
05-13 | VolitionRx Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.92% | 59.64M | |
-27.70% | 9.88B | |
+27.06% | 2.89B | |
-16.78% | 2.88B | |
-15.31% | 2.12B | |
-21.41% | 1.67B | |
+68.70% | 1.45B | |
+29.75% | 788M | |
-5.02% | 741M | |
-29.39% | 514M |
- Stock Market
- Equities
- VNRX Stock
- News VolitionRx Limited
- VolitionRx Limited Signs Global Supply Agreement for Nu.Q® Vet Cancer Test